NCT04573231View on ClinicalTrials.gov

Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

May 24, 2021

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Breast CancerHER2-negative Breast CancerMetastatic Breast Cancer
Interventions
DRUG

18F-DCFPyL

PSMA is highly expressed on prostate cancer and is associated with metastasis and resistance to anti-androgen therapies. Researchers have evaluated the expression of PSMA in the tumor and tumor-associated neovasculature in primary tumors and distant metastases in patients with breast cancer.

Trial Locations (1)

53705

RECRUITING

University of Wisconsin School of Medicine and Public Health, Madison

All Listed Sponsors
lead

University of Wisconsin, Madison

OTHER